Physician profile
Katherine E Matas
NPI 1609936970
$664.54
in general payments reported to CMS, 2019-2025
19 companies · $55.97 in 2025
The $55.97 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $137 · 2024: $472 · 2025: $55.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.39 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.50 | 2024 | Alunbrig, Fruzaqla |
| Lilly USA, LLC | $48.75 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $48.69 | 2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $46.19 | 2023-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $36.04 | 2023-2024 | Keytruda, Lynparza |
| Karyopharm Therapeutics INC. | $34.47 | 2023-2024 | Xpovio |
| Genentech USA, INC. | $32.46 | 2024 | Phesgo, Kadcyla, Perjeta |
| Astellas Pharma US INC | $21.97 | 2024 | Xtandi |
| Janssen Biotech, INC. | $21.21 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $20.75 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.81 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.23 | 2023 | |
| Taiho Oncology, INC. | $17.76 | 2024 | |
| Aveo Pharmaceuticals, INC. | $16.33 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $15.82 | 2024 | |
| Genzyme Corporation | $15.45 | 2023 | |
| Myriad Genetic Laboratories, INC. | $14.60 | 2024 | Myrisk |
| Incyte Corporation | $14.12 | 2024 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Matas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.